Case Information

A lawsuit called In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK is currently pending in the United States District Court for the District of New Jersey (“the Court”). The Lawsuit alleges that Defendants (a complete list of these Defendants is available here) violated numerous state laws by manufacturing, producing and/or selling Valsartan or VCDs that were contaminated with probable genotoxic human carcinogens in the form of nitrosamines, N-nitrosodimethylamine (“NDMA”) and N-nitrosodiethylamine (“NDEA”). This Lawsuit does not include personal injury claims. The Court has not decided whether Defendants did anything wrong and the Defendants have denied any wrongdoing and asserted various legal defenses.

No money or benefits are available now because the Court has not yet decided whether Defendants did anything wrong, and the two sides have not settled the case. There is no guarantee that money or benefits will ever be obtained. For more information on the current status of the case, click here. The United States District Court for the District of New Jersey approved notice for this case, including this website.  To view the Court’s website for this case, click here.

Who Is a Class Member?

Third Party Payor Class
All Third Party Payors that, from at least January 1, 2012 through the date of final recall as of November 10, 2021, paid any amount of money in any of the 50 states, Puerto Rico or the District of Columbia for a valsartan-containing drug that was manufactured, distributed, or sold in the United States by any Active Pharmaceutical Ingredient, Finished Dose, Wholesaler, or Pharmacy Defendant.  Click here for additional information about this class.
In addition to the above Third Party Payor Class, there are two classes relating to individual consumers. 
See descriptions below and separate notices for more details.
Consumer Economic Loss Class Medical Monitoring Class
All individuals in the United States and its territories and possessions who, since at least January 1, 2012 through the date of final recall as of November 10, 2021, paid any amount of money for a valsartan-containing drug (intended for personal or household use) that was manufactured, distributed, or sold by any Defendant. Click here for additional information about this class. Individuals residing in the United States and its territories and possessions (except Mississippi, New Hampshire, North Carolina, and North Dakota) who consumed a sufficiently high Lifetime Cumulative Threshold of NDMA, NDEA, or other nitrosamine, in generic valsartan-containing drugs manufactured by or for Defendants, at least since January 1, 2012. Click here for additional information about this class.

 

Your Legal Rights and Options

Option and Deadline

Your Legal Rights

Do Nothing

no deadline

If you do nothing, you will remain a part of the Class(es) and Lawsuit and you will be bound by any future judgment(s) of the Court.

Exclude Yourself or Opt Out

January 31, 2024

If you take the steps required to exclude yourself from the Classes and Lawsuit, you will not be bound by any future determinations made in the Lawsuit, including any judgments at trial; however, you will also not be eligible for payments or other benefits, if any, that are awarded to any of the Classes by the Court. This is the only option that allows you to pursue your own claims against the Defendants for the legal claims made in this Lawsuit. Complete details about how to opt-out from the Class and Lawsuit are available here.

Register for Updates

If you believe you are eligible, you can complete a simple form here to be informed about case updates. This will help us contact you in the event of any future settlement or judgment.